Compare Halliburton Company (HAL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Summit Therapeutics Inc — how do they compare? Halliburton Company trades at $33.83 (market cap $28.03B), while Summit Therapeutics Inc trades at $15.35 (market cap $11.87B). The key difference: Halliburton Company is far larger — about 2.4× Summit Therapeutics Inc's market cap, and Halliburton Company pays a 2.02% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HAL | SMMT | |
|---|---|---|
Market Cap | $28.03B | $11.87B |
Sector | Energy | Health |
52-Week High | $42.98 | $26.98 |
52-Week Low | $20.97 | $12.55 |
Enterprise Value | $34.18B | $11.20B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.89, down 1.91% amid technical bearish signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue growth driven by international contracts. Valuation metrics remain attractive with P/E of 16.7 and P/S of 1.2, while analyst consensus shows 73% buy ratings with a $43.60 price target. Recent news highlights contract wins in Kuwait and Australia, though Middle East volatility presents near-term headwinds.
HAL offers value with solid earnings momentum and global expansion, but faces execution risks from geopolitical tensions and oil market volatility. The stock's current discount to analyst targets presents opportunity, though technical weakness suggests cautious entry timing. Long-term growth prospects remain intact through technology leadership and international contract pipeline.
Summit Therapeutics (SMMT) trades at $13.96, up 3.1% today, but faces bearish technical signals with negative ROE of -192.5% and net income of -$1.08B for 2025. The company's key catalyst is the FDA review of ivonescimab with a November 2026 decision, supported by expanded clinical trials in bladder and kidney cancer. Cash flow remains dependent on financing activities, with operating cash flow negative at -$323M in 2025.
Investment outlook hinges on ivonescimab's FDA approval, with analyst consensus target at $27.90 offering significant upside. However, high execution risk, ongoing losses, and fiduciary investigations present substantial downside. The stock represents a high-risk biotech speculation with binary outcomes based on regulatory success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
